ISSN 0976-4550  
DOI: 10.21276/Ijabpt  
 
 
 
Peer Reviewed Online International Journal of Applied Biology and Pharmaceutical Technology www.ijabpt.com
 

DOCKING STUDIES OF BCL2 INHIBITORS INVOLVED IN BREAST CANCER  Page No 92 to 101, Volume-8, Issue-3, July-Sept-2017 

Raed Jasim Mohammed

Cancer is one of the world''s leading causes of death and occurs when the homeostatic balance between cell growth and death is disturbed. Cancer has proven to be one of the most intractable diseases to which humans are subjected, and as yet no practical and general effective drugs or methods of control. Therefore, identification of novel potent, selective, and less toxic anticancer agents remains one of the most pressing health problems. Research in cancer biology has discovered that a variety of aberrations in gene expression of anti-apoptotic, pro-apoptotic and BH3-only proteins can contribute to the many forms of the disease. Oxadiazole derivatives have many pharmacological uses i:e compounds possessing oxadiazole moiety acts as an analgesic, hypoglycemic, bactericidal and local anesthetic. Certain 1,3,4-oxadiazole derivatives were reported to possess anti-inflammatory, antitubercular, antifungal, and anticancer activities. In the present research a series of 50 oxadiazole derivatives were designed and evaluated docking studies were performed using Open eye software against cancer proteins of Breast cancer (Intraductal Carcinoma) [B-cell lymphoma 2-BCL2 (1G5M)].

Key words: Breast cancer, BCL2, Oxadiazole, Docking

Pdf
 
 
 
Copyright @ 2010 www.ijabpt.com All rights reserved
Web Counter